Federal Register / Vol. 89, No. 236 / Monday, December 9, 2024 / Notices 97617 

CALENDAR OF REPORTING DATES FOR FLORIDA SPECIAL ELECTIONS—Continued 

Report Close of books 1

Reg./Cert. & 

overnight 

mailing deadline 

Filing deadline 

If Two Elections Are Held, PACs and Party Committees Not Filing Monthly Involved in Only the Special General (04/01/2025) Must File: 

Pre-General ............................................................................................................... 03/12/2025 03/17/2025 03/20/2025 

Post-General .............................................................................................................. 04/21/2025 05/01/2025 05/01/2025 

Mid-Year .................................................................................................................... 06/30/2025 07/31/2025 07/31/2025 

If One Election Is Held, Candidate Committees Involved in the Special General (01/28/2025) Must File: 

Pre-General & Year-End 3 ......................................................................................... 01/08/2025 01/13/2025 01/16/2025 

Post-General .............................................................................................................. 02/17/2025 02/27/2025 02/27/2025 

April Quarterly ............................................................................................................ 03/31/2025 04/15/2025 04/15/2025 

If One Election Is Held, PACs and Party Committees Not Filing Monthly Involved in the Special General (01/28/2025) Must File: 

Pre-General & Year-End 3 ......................................................................................... 01/08/2025 01/13/2025 01/16/2025 

Post-General .............................................................................................................. 02/17/2025 02/27/2025 02/27/2025 

Mid-Year .................................................................................................................... 06/30/2025 07/31/2025 07/31/2025 

1The reporting period always begins the day after the closing date of the last report filed. If the committee is new and has not previously filed 

a report, the first report must cover all activity that occurred before the committee registered as a political committee up through the close of 

books for the first report due. 2 Committees should file a consolidated Pre-Primary & Year-End Report by the filing deadline of the Pre-Primary Report. 

3 Committees should file a consolidated Pre-General & Year-End Report by the filing deadline of the Pre-General Report (if primary not held). 

Dated: December 3, 2024. 

On behalf of the Commission. 

Sean J. Cooksey, 

Chairman, Federal Election Commission. 

[FR Doc. 2024–28771 Filed 12–6–24; 8:45 am] 

BILLING CODE 6715–01–P 

FEDERAL ELECTION COMMISSION 

Sunshine Act Meetings 

TIME AND DATE: Thursday, December 12, 

2024, 10:00 a.m. 

PLACE: Hybrid meeting: 1050 First Street 

NE, Washington, DC (12TH Floor) and 

virtual. 

Note: If you would like to virtually access 

the meeting, see the instructions below. 

STATUS: This meeting will be open to the 

public. To access the meeting virtually, 

go to the Commission’s website 

www.fec.gov and click on the banner to 

be taken to the meeting page. 

MATTERS TO BE CONSIDERED: 

Draft Advisory Opinion 2024–15: 

Unified Libertarians of Massachusetts 

MUR 1604 (Brady Campaign to Prevent 

Gun Violence, et al): 

Recommendation to Relieve the Brady 

Campaign from a Remedial Measure 

in a Conciliation Agreement 

REG 2024–06 (Request to Modify or 

Redact Contributor Info)—Draft 

Notice of Proposed Rulemaking 

Draft Legislative Recommendations 

2024 

Sample LLC Donor Form 

Recommendation That the Office of 

General Counsel Conduct a Review of 

the Agency’s Regulations 

Proposed Revisions to Directives 10 

(Rules of Procedure of the Federal 

Election Commission Pursuant to 2 

U.S.C. 437(c)(e)) and 17 (Circulation 

Authority; Agenda Deadline 

Procedures) 

Election of Officers for 2025 

Management and Administrative 

Matters 

CONTACT PERSON FOR MORE INFORMATION: 

Judith Ingram, Press Officer, Telephone: 

(202) 694–1220. 

Individuals who plan to attend in 

person and who require special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, should contact Laura 

E. Sinram, Secretary and Clerk, at (202) 

694–1040 or secretary@fec.gov, at least 

72 hours prior to the meeting date. 

(Authority: Government in the Sunshine Act, 

5 U.S.C. 552b) 

Laura E. Sinram, 

Secretary and Clerk of the Commission. 

[FR Doc. 2024–28995 Filed 12–5–24; 4:15 pm] 

BILLING CODE 6715–01–P 

FEDERAL MEDIATION AND 

CONCILIATION SERVICE 

Succession Plan for the Federal 

Mediation and Conciliation Service 

AGENCY: Federal Mediation and 

Conciliation Service (FMCS). 

ACTION: Notice of succession plan for the 

FMCS. 

SUMMARY: The Federal Mediation and 

Conciliation Service (FMCS) is issuing 

this notice to inform the public of the 

succession plan for the Federal 

Mediation and Conciliation Service 

(FMCS) provided by the Director of 

FMCS. This notice supersedes all prior 

succession plans issued by the agency 

for officials performing the functions 

and duties of the Director of FMCS. 

DATES: This succession plan for the 

FMCS is effective December 9, 2024. 

FOR FURTHER INFORMATION CONTACT: For 

specific questions related to this notice, 

please contact Greg Goldstein, 202–606– 

8111, ggoldstein@fmcs.gov. 

SUPPLEMENTARY INFORMATION: By the 

authority vested in the Director of the 

Federal Mediation and Conciliation 

Service (FMCS) by 29 U.S.C. 172, and to 

provide for the continuity of essential 

operations of the FMCS in all 

circumstances this Notice provides the 

succession plan of officials authorized 

to perform the functions and duties of 

the Director of the Federal Mediation 

and Conciliation Service. The following 

is the succession plan of officials hereby 

ordered: 

Order of Succession 

During any period in which the 

Director has died, resigned, or otherwise 

become unable to perform the functions 

and duties of the office of the Director, 

and there is no Acting Director serving 

under the Federal Vacancies Reform Act 

of 1998, 5 U.S.C. 3345–3349d, the 

following officers of the FMCS, in the 

order listed, are hereby delegated the 

authority to perform the functions and 

duties of the Director, to the extent 

permitted by law: 


ddrumheller on DSK120RN23PROD with NOTICES1
97618 Federal Register / Vol. 89, No. 236 / Monday, December 9, 2024 / Notices 

1. Principal Deputy, Chief Operating 

Officer; 

2. Deputy Director, Field Operations; 

3. Deputy Director for Labor Policy 

and Communications; 

4. Director, Procurement and 

Operational Support; 

5. General Counsel; 

6. Associate Deputy Director for Field 

Operations, National; 

7. Associate Deputy Director for Field 

Operations, Regional; 

8. Director, Human Resources; and 

9. Director, Budget. 

No individual who is serving in an 

office listed in this order in an acting 

capacity, by virtue of so serving, shall be 

delegated the functions and duties of 

the Director. 

Dated: December 4, 2024. 

Gregory Goldstein, 

Chief Operating Officer Performing the Duties 

of the Director. 

[FR Doc. 2024–28847 Filed 12–6–24; 8:45 am] 

BILLING CODE 6732–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Supplemental Evidence and Data 

Request on Medical Care for Adults 

With Down Syndrome 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Request for supplemental 

evidence and data submission. 

SUMMARY: The Agency for Healthcare 

Research and Quality (AHRQ) is seeking 

scientific information submissions from 

the public. Scientific information is 

being solicited to inform our review on 

Medical Care for Adults with Down 

Syndrome, which is currently being 

conducted by the AHRQ’s Evidencebased Practice Centers (EPC) Program. 

Access to published and unpublished 

pertinent scientific information will 

improve the quality of this review. 

DATES: Submission Deadline on or 

before January 8, 2025. 

ADDRESSES: 

Email submissions: epc@

ahrq.hhs.gov. 

Print submissions: 

Mailing Address: Center for Evidence 

and Practice Improvement, Agency for 

Healthcare Research and Quality, 

ATTN: EPC SEADs Coordinator, 5600 

Fishers Lane Mail Stop 06E53A, 

Rockville, MD 20857 

Shipping Address (FedEx, UPS, etc.): 

Center for Evidence and Practice 

Improvement, Agency for Healthcare 

Research and Quality, ATTN: EPC 

SEADs Coordinator, 5600 Fishers Lane, 

Mail Stop 06E77D, Rockville, MD 

20857. 

FOR FURTHER INFORMATION CONTACT: 

Kelly Carper, telephone: 301–427–1656 

or email: epc@ahrq.hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

Agency for Healthcare Research and 

Quality has commissioned the 

Evidence-based Practice Centers (EPC) 

Program to complete a review of the 

evidence for Medical Care for Adults 

with Down Syndrome. AHRQ is 

conducting this review pursuant to 

section 902 of the Public Health Service 

Act, 42 U.S.C. 299a. 

The EPC Program is dedicated to 

identifying as many studies as possible 

that are relevant to the questions for 

each of its reviews. In order to do so, we 

are supplementing the usual manual 

and electronic database searches of the 

literature by requesting information 

from the public (e.g., details of studies 

conducted). We are looking for studies 

that report on Medical Care for Adults 

with Down Syndrome. The entire 

research protocol is available online at: 

https://effectivehealthcare.ahrq.gov/ 

products/care-adults-down-syndrome/ 

protocol. 

This is to notify the public that the 

EPC Program would find the following 

information on Medical Care for Adults 

with Down Syndrome helpful: 

D A list of completed studies that 

your organization has sponsored for this 

topic. In the list, please indicate 

whether results are available on 

ClinicalTrials.gov along with the 

ClinicalTrials.gov trial number. 

D For completed studies that do not 

have results on ClinicalTrials.gov, a 

summary, including the following 

elements, if relevant: study number, 

study period, design, methodology, 

indication and diagnosis, proper use 

instructions, inclusion and exclusion 

criteria, primary and secondary 

outcomes, baseline characteristics, 

number of patients screened/eligible/ 

enrolled/lost to follow-up/withdrawn/ 

analyzed, effectiveness/efficacy, and 

safety results. 

D A list of ongoing studies that your 

organization has sponsored for this 

topic. In the list, please provide the 

ClinicalTrials.gov trial number or, if the 

trial is not registered, the protocol for 

the study including, if relevant, a study 

number, the study period, design, 

methodology, indication and diagnosis, 

proper use instructions, inclusion and 

exclusion criteria, and primary and 

secondary outcomes. 

D Description of whether the above 

studies constitute ALL Phase II and 

above clinical trials sponsored by your 

organization for this topic and an index 

outlining the relevant information in 

each submitted file. 

Your contribution is very beneficial to 

the Program. Materials submitted must 

be publicly available or able to be made 

public. Materials that are considered 

confidential; marketing materials; study 

types not included in the review; or 

information on topics not included in 

the review cannot be used by the EPC 

Program. This is a voluntary request for 

information, and all costs for complying 

with this request must be borne by the 

submitter. 

The draft of this review will be posted 

on AHRQ’s EPC Program website and 

available for public comment for a 

period of 4 weeks. If you would like to 

be notified when the draft is posted, 

please sign up for the email list at: 

https://effectivehealthcare.ahrq.gov/ 

email-updates. 

The review will answer the following 

questions. This information is provided 

as background. AHRQ is not requesting 

that the public provide answers to these 

questions. 

Key Questions (KQ) 

1. What are the benefits, harms, and 

considerations of screening and 

diagnostic interventions, for cooccurring medical and behavioral health 

conditions in adults with Down 

syndrome? 

2. What are the benefits and harms, 

and considerations of interventions to 

treat co-occurring medical and 

behavioral health conditions 

specifically in adults with Down 

syndrome? 

Contextual Questions (CQ) 

1. What conditions occur at an 

increased or decreased prevalence in 

adults with Down syndrome compared 

to the general adult population. How 

does prevalence vary by age/decade of 

age, gender, setting (rural), and race/ 

ethnicity? 

2. How do clinical symptoms and the 

presentation of common co-occurring 

behavioral/mental health conditions 

(e.g., anxiety and depression) differ 

among adults with Down syndrome 

compared to their presentation in the 

general adult population? 


ddrumheller on DSK120RN23PROD with NOTICES1